CREATE Medicines
CREATE Medicines is a clinical-stage biotechnology company pioneering in vivo CAR therapies through proprietary mRNA-LNP immune cell programming, directly engineering T cells, NK cells, and myeloid cells inside the body to treat oncology and autoimmune disease patients.
- Company typePrivate
- Founded2019
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What CREATE Medicines does
CREATE Medicines is a clinical-stage biotechnology company pioneering in vivo CAR therapies through a proprietary mRNA-lipid nanoparticle (mRNA-LNP) platform that programs immune cells directly inside the body, eliminating the need for ex vivo cell harvesting or lymphodepletion conditioning. Founded in 2019 and headquartered at 300 Technology Square in Cambridge, Massachusetts, the company was previously known as Myeloid Therapeutics before rebranding in fall 2025 to reflect the platform's expanded scope across T cells, NK cells, and myeloid cells and its entry into autoimmune disease alongside oncology. The company maintains 11–50 employees and has dosed more than 50 patients across its clinical programs, which represents the largest clinical dataset in the in vivo CAR field.
The core technology stack comprises three differentiated layers: a redosable mRNA-LNP delivery system, a multi-immune CAR architecture that programs T, NK, and myeloid cells simultaneously, and the RetroT platform — an all-RNA genome integration system using human LINE-1 retrotransposon machinery to enable site-specific genetic payload insertion without viral vectors or double-strand breaks. The pipeline includes four clinical-stage oncology assets (MT-302 targeting TROP2 in frontline gastroesophageal cancer, MT-303 targeting GPC3 in frontline hepatocellular carcinoma, MT-304 targeting HER2 across multiple solid tumors, and CRT-401 targeting HER2 x TROP2) and two preclinical autoimmune assets (CRT-402 targeting CD19 and CRT-403 targeting CD19 x BCMA via the RetroT platform).
CREATE Medicines is pre-revenue and generates no product sales, with future revenue expected to flow through pharmaceutical product sales and partnership/licensing transactions contingent on regulatory approval. Go-to-market activity is conducted through clinical collaborations (most prominently with Amsterdam University Medical Center for MT-302 in frontline GEJ), business development outreach via [email protected], and presence at major industry venues including J.P. Morgan Healthcare Conference, AACR, SITC, and Keystone Symposia. The company is venture-backed by Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners, and Alexandria Venture Investments, and led by founder and CEO Daniel Getts, Executive Chairman Ron Philip, and a senior team recruited from IDEAYA, Bristol Myers Squibb, Vertex, TCR2, EMD Serono, and Spark Therapeutics.
CREATE Medicines firmographics
Firmographics- Name
- CREATE Medicines
- Legal name
- CREATE Medicines, Inc.
- Website
- https://createmedicines.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CREATE Medicines is a clinical-stage biotechnology company pioneering in vivo CAR therapies through proprietary mRNA-LNP immune cell programming, directly engineering T cells, NK cells, and myeloid cells inside the body to treat oncology and autoimmune disease patients.
- Ownership category
- akta.pro rank
CREATE Medicines industry classification
Industry- Product category
- In Vivo CAR Immunotherapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
- akta.pro secondary industries
- CAR-T & TCR-T Therapies (HLAAABAC), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)
Keywords
Where CREATE Medicines is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CREATE Medicines business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Therapeutic Product Sales: As a clinical-stage biotechnology company, CREATE Medicines does not yet have commercial products. The company is developing in vivo CAR therapies for oncology and autoimmune diseases. If products receive regulatory approval, revenue would be generated through pharmaceutical product sales.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
CREATE Medicines product offering
Product offeringCore offering
CREATE Medicines is a clinical-stage biotechnology company developing in vivo CAR (chimeric antigen receptor) therapies that program immune cells directly inside the body using its proprietary mRNA-Lipid Nanoparticle (mRNA-LNP) platform. Its pipeline spans solid tumor oncology programs (MT-302 for TROP2-positive gastroesophageal cancer, MT-303 for GPC3 hepatocellular carcinoma, MT-304 for HER2-positive solid tumors, CRT-401 for HER2 x TROP2) and B cell-driven autoimmune disease programs (CRT-402 for CD19, CRT-403 for CD19 x BCMA). The RetroT platform provides all-RNA genome integration for durable gene engineering without viral vectors.
Product overview
CREATE Medicines is a clinical-stage biotechnology company pioneering an in vivo immune programming platform based on proprietary mRNA-LNP CAR technology. The platform enables direct programming of T cells, NK cells, and myeloid cells inside the body, producing scalable, repeat-dose, off-the-shelf immunotherapies. The company operates a multi-product portfolio spanning oncology and autoimmune disease: clinical-stage programs include MT-302 (TROP2-targeted for gastroesophageal cancer), MT-303 (GPC3-targeted for hepatocellular carcinoma), MT-304 (HER2-targeted multi-immune therapy for breast/gastric cancers), and CRT-401 (HER2 x TROP2 multi-immune CAR). Preclinical programs include CRT-402 (CD19 CAR-T for autoimmune disease) and CRT-403 (dual CD19 x BCMA CAR for autoimmune disease using RetroT technology). The RetroT platform is an all-RNA genome integration system using LINE-1 retrotransposon machinery for stable gene delivery without viral vectors.
Differentiator
Problem solved
Functional benefit
Products and services
- MT-302 In vivo CAR therapy targeting TROP2 for frontline gastroesophageal junction (GEJ) cancer. Programs myeloid cells using CREATE's redosable mRNA-LNP system. Demonstrated proof-of-mechanism and early anti-tumor activity in first-in-human studies.
- MT-303 In vivo GPC3-targeted CAR therapy for first-line metastatic hepatocellular carcinoma (HCC). Evaluated in combination with standard immunotherapies to achieve deeper, durable responses.
- MT-304 First-in-class multi-immune in vivo HER2-targeted CAR therapy that simultaneously programs NK and myeloid cells using CREATE's mRNA-LNP platform. Designed for HER2-positive breast cancer and other HER2-positive solid tumors including gastric cancer.
- CRT-401 Multi-immune in vivo CAR therapy targeting both HER2 and TROP2 antigens, simultaneously programming T cells, NK cells, and myeloid cells using the proprietary mRNA-LNP platform.
- CRT-402 CD19-targeted in vivo CAR-T therapy for autoimmune disease. Demonstrated deep and durable B cell depletion in non-human primates, with potential for immune reset through repeat dosing flexibility. Advancing toward clinical entry for B cell-driven autoimmune indications.
- CRT-403 Dual CAR CD19 x BCMA directed therapy utilizing the RetroT platform, designed to broaden therapeutic reach across refractory autoimmune indications.
- RetroT Platform All-RNA genome integration platform using human LINE-1 retrotransposon machinery for site-specific genetic payload insertion without DNA double-strand breaks or viral vectors. Enables stable, durable cell engineering in vivo as the foundation for durable CAR expression in pipeline assets such as CRT-403.
- mRNA-LNP CAR Platform Proprietary mRNA-lipid nanoparticle (LNP) platform that enables direct programming of T cells, NK cells, and myeloid cells within the body. Supports repeatable dosing without lymphodepletion or ex vivo manufacturing, and underpins all of CREATE's in vivo CAR clinical and preclinical programs.
Quantifiable outcome
- Complete B cell depletion demonstrated in non-human primates with proprietary in vivo CAR-T platform
- +3 more outcomes
Companies that use CREATE Medicines
Customer profileSegments3 records
Ideal customer profiles2 records
CREATE Medicines technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
CREATE Medicines partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Amsterdam University Medical CentercoreClinical collaboration where Amsterdam UMC dosed the first patient in a clinical trial evaluating CREATE's MT-302 in vivo CAR therapy combined with standard front-line treatments for advanced gastroesophageal cancer. The trial assesses safety, tolerability, and preliminary efficacy, marking a significant step toward scalable, off-the-shelf cell therapies for solid tumors.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
CREATE Medicines competitors and assessment
Company assessmentDirect peers
- Capstan Therapeutics: Capstan is a direct peer pursuing in vivo CAR-T cell engineering using mRNA-LNP delivery to reprogram immune cells inside the body. Both companies target the same core thesis: replacing ex vivo CAR-T manufacturing with in vivo programming for oncology and autoimmune indications.
- Umoja Biopharma: Umoja is developing in vivo CAR-T cell therapies using a proprietary platform to generate CAR-T cells in vivo, directly comparable to CREATE's mRNA-LNP approach. Both target oncology and autoimmune indications with off-the-shelf, repeat-dose potential.
- Cartesian Therapeutics: Cartesian is a clinical-stage developer of RNA cell therapy engineering, including mRNA-based CAR-T approaches. Its Descartes-08 program (anti-BCMA) targets autoimmune disease with similar mechanism to CREATE's CRT-402/CRT-403 CD19/BCMA programs.
Broad incumbents
- Allogene Therapeutics: Allogene is a leading allogeneic CAR-T developer with broader portfolio across hematologic malignancies and solid tumors. While focused on ex vivo manufacturing rather than in vivo, it is a major competitive incumbent shaping the cell therapy landscape CREATE is targeting.
- Caribou Biosciences: Caribou develops allogeneic CAR-T cell therapies using CRISPR gene editing, with clinical programs in hematologic malignancies. It represents a broader CAR-T incumbent focused on next-generation engineered cell therapy approaches.
- CRISPR Therapeutics: CRISPR Therapeutics is a leading gene-editing biotech with Casgevy (the first approved CRISPR therapy) and a broader pipeline including CAR-T programs. It is a broad incumbent in the engineered cell therapy space relevant to CREATE's in vivo CAR approach.
- Intellia Therapeutics: Intellia is a clinical-stage gene editing company developing in vivo CRISPR/Cas9 therapies. While primarily focused on gene editing rather than CAR delivery, it is broadly comparable as an in vivo genetic medicine platform targeting similar patient populations.
Emerging players
- Beam Therapeutics: Beam is a clinical-stage developer of base editing therapies for hematologic and other diseases. As a next-generation genetic medicine platform, it represents an emerging alternative approach to cell engineering with partial overlap in target indications.
- Precision Biosciences: Precision Bio develops allogeneic CAR-T therapies using its proprietary ARCUS gene editing platform. Its focus on off-the-shelf cell therapies for oncology and autoimmune diseases provides partial overlap with CREATE's in vivo CAR strategy.
Others
- Moderna: Moderna is the leading mRNA-LNP platform company with extensive delivery technology expertise. While primarily focused on vaccines and protein replacement rather than in vivo CAR, it is a key ecosystem participant and potential partner/licensor in the mRNA-LNP space underpinning CREATE's platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
CREATE Medicines social profiles
Digital presenceCREATE Medicines financial estimates
Financial estimateRevenue estimate
Valuation estimate
CREATE Medicines leadership team
Management profileNumber of profiles
Profiles12 records
CREATE Medicines funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CREATE Medicines M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CREATE Medicines
What does CREATE Medicines do?
CREATE Medicines is a clinical-stage biotechnology company developing in vivo CAR (chimeric antigen receptor) therapies that program immune cells directly inside the body using its proprietary mRNA-Lipid Nanoparticle (mRNA-LNP) platform. Its pipeline spans solid tumor oncology programs (MT-302 for TROP2-positive gastroesophageal cancer, MT-303 for GPC3 hepatocellular carcinoma, MT-304 for HER2-positive solid tumors, CRT-401 for HER2 x TROP2) and B cell-driven autoimmune disease programs (CRT-402 for CD19, CRT-403 for CD19 x BCMA). The RetroT platform provides all-RNA genome integration for durable gene engineering without viral vectors.
Is CREATE Medicines a public or private company?
CREATE Medicines is a private company. It is classified as venture growth investor backed and is currently operating.
When was CREATE Medicines founded?
CREATE Medicines was founded in 2019. It employs 11 to 50 people.
Where is CREATE Medicines based?
CREATE Medicines is headquartered in Cambridge, United States, in the North America region.
How does CREATE Medicines make money?
One revenue line is on record: therapeutic Product Sales.
Who are CREATE Medicines's main competitors?
Direct peers on record are Capstan Therapeutics, Umoja Biopharma and Cartesian Therapeutics. Broad incumbents are Allogene Therapeutics, Caribou Biosciences, CRISPR Therapeutics and Intellia Therapeutics. Emerging players are Beam Therapeutics and Precision Biosciences. Moderna is listed as an others.
Does CREATE Medicines have an API?
No public API is recorded for CREATE Medicines.
What industry is CREATE Medicines in?
CREATE Medicines's product category is In Vivo CAR Immunotherapy. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 541714 and its SIC code is 2834.